When we think about science, we often imagine a universal language of knowledge in the form of a shared code of numbers, graphs, and precise words that transcend borders. But what happens when the language of science is not the language of the scientist? This is the challenge explored in a recent study by a group of publication professionals from the pharmaceutical and medical communications industries across the Asia Pacific region. The study looked at how researchers in this region navigate the world of English-language scientific publishing. Their findings remind us that words matter, and the language we use can either invite voices into global conversations and knowledge exchange, or keep them out.

Most of us never give much thought to the small artery that runs along the inside of our wrist, the radial artery. You can feel it easily if you press your fingers just below your thumb. Yet in modern medicine, this little vessel has become one of the most important gateways to the heart. Imagine a doctor threading a tiny tube, called a catheter, through the radial artery to reach your heart. This technique, called transradial access, has transformed modern cardiology. By entering through the radial artery, doctors can perform life-saving cardiac procedures with fewer complications, faster recovery, and even lower costs than older methods that went through the leg. Many people can even walk out of the hospital on the same day. Over the past two decades, doctors have increasingly chosen the radial artery as their entry point for procedures like angiography (imaging of the heart’s blood vessels) and angioplasty (opening blocked arteries). But there’s a catch: sometimes the artery rebels. It tightens suddenly, almost like a muscle cramp, gripping the medical instruments and making the doctor’s job harder. This is known as radial artery spasm (or RAS for short). In rare cases, the spasm is so severe that it traps the catheter or damages the artery wall.

Imagine a future where treating cancer doesn’t just depend on high-tech machines or potent drugs, but also on something as simple, and as complex, as the bacteria living in your gut. This future might be closer than we think, thanks to groundbreaking research led by Professor Andrea Facciabene at the University of Pennsylvania. In a randomized pilot study recently published in the Journal for ImmunoTherapy of Cancer, Prof. Facciabene and an international team of researchers explored a curious and compelling idea: could altering the gut microbiome enhance the effectiveness of radiation therapy in patients with inoperable early-stage lung cancer? The answer, at least in this early stage, appears to be yes.